<DOC>
	<DOCNO>NCT01441687</DOCNO>
	<brief_summary>This randomize pilot phase I trial study best way , either express prostatic secretion ( EPS ) post massage urine ( PMU ) biomarkers , predict biopsy result patient undergoing prostate biopsy . Studying sample urine laboratory may help doctor detect prostate cancer . It yet know whether EPS PMU biomarkers effective predict prostate biopsy result</brief_summary>
	<brief_title>Comparing Reliability Expressed Prostatic Secretion ( EPS ) Post Massage Urine ( PMU ) Prediction Prostate Cancer Biopsy Outcome</brief_title>
	<detailed_description>OBJECTIVES : I . To determine non-invasive test prostate cancer , EPS PMU , good predictor prostate cancer biopsy result . ( Part I ) II . To determine whether standardized test transmembrane protease , serine 2 ( TMPRSS2 ) : ERG Types III VI superior test TMPRSS2 : ERG Type III predict prostate biopsy outcome . ( Part I ) III . To expand sample size utilizing best TMPRSS2 : ERG test best specimen type determine objective I II order estimate reasonable accuracy positive predictive value ( PPV ) negative predictive value ( NPV ) test . ( Part II ) IV . To expand biomarker set , include Prostate Cancer Antigen 3 ( PCA3 ) -ribonucleic acid ( RNA ) , d-glyceraldehyde-3-phosphate dehydrogenase ( GADPH ) -RNA , prostate-specific antigen ( PSA ) -RNA , deoxyribonucleic acid ( DNA ) methylation level glutathione s-transferase pi ( GSTP1 ) , adenomatous polyposis coli ( APC ) , retinoic acid receptor beta ( RARB ) , Mitochondrial DNA ( MT-DNA ) Deletions ra association ( RalGDS/AF-6 ) domain family 1 ( RASSF1 ) , develop extensive data set use multivariate analysis . ( Part II ) V. Use multivariate analysis determine combination molecular marker offer great improvement ability predict biopsy outcome current baseline predictor ( Serum PSA digital rectal examination [ DRE ] ) . ( Part II ) VI . Estimate PPV NPVs analysis compare standard assay 's performance . ( Part II ) OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive digital rectal palpation void spontaneous urine sample PMU analysis . Patients undergo prostate biopsy . ARM II : Patients receive DRE prostatic massage 30-60 second milk urethra provide collection EPS . Patients undergo prostate biopsy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>All men undergo transrectal ultrasound prostate ( TRUSP ) biopsy department Urology participate urology clinic evaluation prostate cancer Men previous diagnosis prostate cancer Men without prior diagnosis prostate cancer previously undergone biopsy suspicious DRE PSA Men prior diagnosis cancer &lt; 5 year ago , exclude basal cell carcinoma and/or squamous cell carcinoma</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Health status unknown</keyword>
	<keyword>healthy , evidence disease</keyword>
</DOC>